Superoxide dismutase activity in early and advanced Parkinson's disease

Functional Neurology

Volumn 12, Issue 2, 1997, Pages 63-68

  Bostantjopoulou, Sevasti ^a,b   Kyriazis, George ^a   Katsarou, Zoe ^a   Kiosseoglou, Grigoris ^a   Kazis, Aristides ^a   Mentenopoulos, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

L Dopa; oxidant stress; Parkinson's disease; superoxide dismutase

Indexed keywords

SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; ONSET AGE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS;

AGED; ANTIPARKINSON AGENTS; BROMOCRIPTINE; ERYTHROCYTES; FEMALE; HEMOGLOBINS; HUMANS; LEVODOPA; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; SELEGILINE; SUPEROXIDE DISMUTASE;

EID: 0030921419     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40 (Suppl 3):32-37
2. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812
3. Halliwell B, Cutteridge JMC. Oxygen radical and the nervous system. Trends Neurosci 1985;8:22-26
4. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442
5. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M eds Recent developments in Parkinson's disease. Vol. 2. Florahne Park, NJ; Macmillan Health Care Information 1987:153-164
6. McCord JM, Fridovich I. Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969; 244:6049-6055
7. Arthur JR, Boyne R. Superoxide dismutase and glutathione peroxidase activities in neutrophils from selenium deficient and copper deficient cattle. Life Sci 1985; 36:1569-1575
8. Armitage P, Berry G. Statistical methods in medical research. Second edition. Oxford; Blackwell Scientific Publications 1987:150-152 and 186-205
9. Dexter DT, Holley AE, Flitter WD et al. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994; 9:92-97.
10. Sian J, Dexter DT, Lees AJ et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355
11. Beal MF. Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-366
12. Calne DB. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol 1992;32:799-803
13. Ahlskog JG, Mitti RJ, Low PA et al. No evidence for systemic oxidant stress in Parkinson's disease or Alzheimer's disease. Mov Disord 1995;10:566-573
14. Saggu H, Cooksey J, Dexter DT et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697
15. Marttila RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 1988;86:321-331
16. Yahara O, Hashimoto K, Taniguchi N et al. Serum manganese-super oxide dismutase in patients with neuromuscular disorders as judged by an ELISA. Res Commun Chem Pathol Pharmacol 1991;72:315-326
17. Checkaway H, Costa LG, Woods JS, Castoldi AF, Lund BO, Swanson PD. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992;4:283-290
18. Karla J, Rajput AH, Mantha SV, Prasad K. Serum antioxidant enzyme activity in Parkinson's disease. Mol Cell Biochem 1992;110:165-168
19. Urakami K, Sano K, Matsushima E et al. Decreased superoxide dismutase activity in erythrocytes in Parkinson's disease. Jpn J Psychiatry Neurol 1992;46:933-936
20. Poirier J, Barbeau A. Erythrocyte antioxidant activity in human patients with Parkinson's disease. Neurosci Lett 1987; 75:345-348
21. Dahn HC, Benedetti MS, Dostert P. Differential changes in superoxide dismutase activity in brain and liver of old rats and mice. J Neurochem 1983;40:1003-1007
22. Vanella A, Geremia E, D'Urso G et al. Superoxide dismutase activities in aging rat brain. Gerontology 1982;28:108-113
23. Marttila RJ, Roytta M, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in the human brain. J Neural Transm Gen Sect 1988; 74: 87-95
24. Sandler M. Dopaminergic neuroprotection. In: Sandler M ed Parkinson's disease: symposium review 1992. London: John Libbey and Company Ltd. 1993: 49-58
25. Knoll J. The pharmacology of selegiline ((-) deprenyl): New aspects. Acta Neurol Scand 1989;80(Suppl 126):83-91
26. Sandler M, Glover V, Clow A, Jarman J. Monoamine oxidase-B, monoamine oxidase-B inhibitors and Parkinson's disease: a role for Superoxide dismutase? Adv Neurol 1993;60:238-241
27. Kushleika J, Checkaway H, Woods J et al. Selegiline and lymphocyte Superoxide dismutase activities in Parkinson's disease. Ann Neurol 1996;39:378-381
28. Baronti F, Davis T, Boldry R, Mouradian M, Chase T. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992;42:541-544
29. Ogawa N, Edamatsu R, Mizukawa K, Asanuma M, Kohno M, Mori A. Degeneration of dopaminergic neurons and free radicals: possible participation of levodopa. Adv Neurol 1993;60:242-258